



Company Announcement no. 09/2008

To: OMX Nordic Exchange Copenhagen

Hørsholm, Denmark, March 14, 2008

LifeCycle Pharma Increases Share Capital by 334,469 Shares as a Consequence of the Exercise of Employee Warrants

Summary: LifeCycle Pharma increases its share capital by nom. 334,469 shares as a consequence of the exercise of warrants.

LifeCycle Pharma A/S (OMX: LCP) has decided to increase its share capital by nom. 334,469 shares as a consequence of the exercise of warrants. The increase is effected without any pre-emption rights for the existing shareholders of the company or others.

The shares are subscribed in cash as follows: (1) Nom. 80,000 shares are subscribed against payment of DKK 2.5 per share of nom. DKK 1. (2) Nom. 250,636 shares are subscribed against payment of DKK 7.885 per share of nom. DKK 1. (3) Nom. 3,883 shares are subscribed against payment of DKK 22.3 per share of nom. DKK 1. Gross proceeds to the company are DKK 2,261,740. The increase corresponds to approx. 1.04 % of the company's share capital after the increase. The new shares are ordinary bearer shares without any special rights and are freely transferable negotiable instruments. The new shares shall give rights to dividends and other rights in relation to the company from the date of the registration of the capital increase with the Commerce and Companies Agency. The new shares will be listed on the OMX after registration with the said agency. The company's current share capital amounts to DKK 31,770,705 shares and will after the capital increase be DKK 32,105,174. The capital increase is expected to be finalized shortly.

About LifeCycle Pharma A/S ("LCP")

LCP is an emerging specialty pharmaceutical company that, through innovative technologies, is able to rapidly develop a portfolio of differentiated products to meet the unique needs of key therapeutic markets and patient populations. This includes products for immunosuppression, specifically organ transplantation, and to combat certain cardiovascular diseases. By using its unique and patented delivery technology, MeltDose®, LCP is able to develop drugs with enhanced absorption and thereby increased bioavailability. LCP has a cholesterol lowering product, Fenoglide™, currently on the U.S. market and a diversified near- and medium-term pipeline, including five product candidates in clinical trials and three in preclinical stages of development. LCP is listed on the OMX Nordic Exchange Copenhagen under the trading symbol (OMX: LCP).

LIFECYCLE PHARMA A/S	TEL. +45 7033 3300
KOGLE ALLÉ 4	FAX +45 3613 0319
DK-2970 HØRSHOLM	CVR. 26 52 77 67
WWW.LIFECYCLEPHARMA.COM	INFO@LCPHARMA.COM

page 1 of 2



For further information, please visit www.lcpharma.com.

For further information please contact LifeCycle Pharma A/S:

Flemming Ornskov, MD President and CEO +45 2420 0368; FO@lcpharma.com	or: Hans Christian Teisen Senior Vice President & CFO +45 20 30 69 85; E-mail: hct@lcpharma.com
---	--

LIFECYCLE PHARMA A/S
KOGLE ALLÉ 4
DK-2970 HØRSHOLM
WWW.LIFECYCLEPHARMA.COM

TEL. +45 7033 3300
FAX +45 3613 0319
CVR. 26 52 77 67
INFO@LCPHARMA.COM

page 2 of 2